This inability to reasonably identify p53-mutant CLL at diagnosis limits our understanding of how p53 mutations impact therapeutic responses and outcomes, and challenges our ability to design adequate clinical trials for this patient population. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.